Senti Biosciences, a South San Francisco, Calif.-based the synthetic biology company developing adaptive therapies for important diseases, completed a $53M Series A round of funding.
The round was led by New Enterprise Associates, with participation from 8VC, Amgen Ventures, Pear Ventures, Lux Capital, Menlo Ventures, Allen & Company, Nest.Bio, Omega Funds, Goodman Capital, and LifeForce Capital.
The company intends to use the funds to grow their therapeutic design platform and advance therapeutic candidates towards the clinic.
Led by Dr. Tim Lu, co-founder and CEO, Senti Biosciences designs synthetic gene circuits for adaptive cell and gene therapies to treat pressing diseases. The company’s technology platform – that builds off of nearly two decades of its team’s pioneering synthetic biology research across MIT, the Wyss Institute at Harvard, MD Anderson, Boston University, ETH Zurich, and other institutions – enables the company to design, build, and test various genetic circuits to enhance human cell and gene therapies. These adaptive therapies can act locally, sense-and-respond to a variety of disease conditions, be controlled externally, and implement multi-factorial therapeutic functions.
Senti is a resident company of Johnson & Johnson Innovation, JLABS at South San Francisco (JLABS @ SSF).